(±)-cis-1-benzyl-4-(hydroxymethyl)piperidin-3-ol | 39478-61-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (±)-cis-1-benzyl-4-(hydroxymethyl)piperidin-3-ol
• 英文别名: (+/-)-cis-1-Benzyl-4-(hydroxymethyl)piperidin-3-ol；(3RS,4SR)-1-benzyl-4-(hydroxymethyl)piperidin-3-ol；rac-cis-1-benzyl-4-(hydroxymethyl)piperidin-3-ol；1-benzyl-4c-hydroxymethyl-piperidin-3r-ol；cis-N-Benzyl-4-hydroxymethyl-3-hydroxypiperidin；(3R,4S)-1-benzyl-4-(hydroxymethyl)piperidin-3-ol
• CAS: 39478-61-0；41632-37-5；41632-38-6；58322-72-8
• 化学式: C₁₃H₁₉NO₂
• 分子量: 221.299
• InChiKey: PAZOUOCFOKZLSA-STQMWFEESA-N

物化性质

• 沸点：
  361.5±32.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  43.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (±)-cis-1-benzyl-4-(hydroxymethyl)piperidin-3-ol 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 15.0h， 生成 rac-cis-4-(hydroxymethyl)-1-methylpiperidin-3-ol
  参考文献：
  名称：

  2,4-Dioxa-7-aza-，2,4-Dioxa-8-aza-和2,4-Dioxa-9-aza-3-phosphadecalins作为刚性乙酰胆碱模拟物：合成与表征

  摘要：

  合适的哌啶前体的磷酸化产生了一系列新型十氢化萘型O，N，P-杂环。标题化合物为P（3）轴向和P（3）赤道X取代，顺式和反式构型的2,4-dioxa-7-aza-，2,4-dioxa-8-aza-和2,4-二氧杂-9-氮杂-3-磷酸双环[4.4.0]癸烷3-氧化物（X = Cl，F，4-硝基苯氧基和2,4-二硝基苯氧基）被构型固定且构象受限的P-类似物乙酰胆碱的“甲氧基” ，因此代表乙酰胆碱（7-氮杂和9-氮杂异构体）或γ-均-乙酰胆碱模拟物（8-氮杂异构体）。作为乙酰胆碱酯酶（AChE）的不可逆抑制剂，这些化合物被认为是研究31抑制作用的立体化学过程的合适探针。P-NMR光谱。此外，这些模拟物的设计将使人们能够研究与AChE的分子相互作用，特别是乙酰胆碱的识别构象。

  DOI：

  10.1002/hlca.200490236
• 作为产物：
  描述：

  N-苄基-3-氧代哌啶-4-羧酸乙酯盐酸盐 在 sodium hydroxide 、 sodium tetrahydroborate 作用下， 以 甲醇 、 水 为溶剂， 反应 35.0h， 生成 (±)-cis-1-benzyl-4-(hydroxymethyl)piperidin-3-ol
  参考文献：
  名称：

  2,4-Dioxa-7-aza-，2,4-Dioxa-8-aza-和2,4-Dioxa-9-aza-3-phosphadecalins作为刚性乙酰胆碱模拟物：合成与表征

  摘要：

  合适的哌啶前体的磷酸化产生了一系列新型十氢化萘型O，N，P-杂环。标题化合物为P（3）轴向和P（3）赤道X取代，顺式和反式构型的2,4-dioxa-7-aza-，2,4-dioxa-8-aza-和2,4-二氧杂-9-氮杂-3-磷酸双环[4.4.0]癸烷3-氧化物（X = Cl，F，4-硝基苯氧基和2,4-二硝基苯氧基）被构型固定且构象受限的P-类似物乙酰胆碱的“甲氧基” ，因此代表乙酰胆碱（7-氮杂和9-氮杂异构体）或γ-均-乙酰胆碱模拟物（8-氮杂异构体）。作为乙酰胆碱酯酶（AChE）的不可逆抑制剂，这些化合物被认为是研究31抑制作用的立体化学过程的合适探针。P-NMR光谱。此外，这些模拟物的设计将使人们能够研究与AChE的分子相互作用，特别是乙酰胆碱的识别构象。

  DOI：

  10.1002/hlca.200490236

文献信息

• Radiolabelling of 1,4-disubstituted 3-[18F]fluoropiperidines and its application to new radiotracers for NR2B NMDA receptor visualization
  作者：Radouane Koudih、Gwénaëlle Gilbert、Martine Dhilly、Ahmed Abbas、Louisa Barré、Danièle Debruyne、Franck Sobrio

  DOI：10.1039/c2ob26378e

  日期：——

  In order to develop a novel and useful building block for the development of radiotracers for positron emission tomography (PET), we studied the radiolabelling of 1,4-disubstituted 3-[18F]fluoropiperidines. Indeed, 3-fluoropiperidine became a useful building block in medicinal chemistry for the pharmacomodulation of piperidine-containing compounds. The radiofluorination was studied on substituted piperidines with electron-donating and electron-withdrawing N-substituents. In the instance of electron-donating N-substituents such as benzyl or butyl, configuration retention and satisfactory fluoride-18 incorporation yields up to 80% were observed. In the case of electron-withdrawing N-substituents leading to carbamate or amide functions, the incorporation yields depend on the 4-susbtitutent (2 to 63%). The radiolabelling of this building block was applied to the automated radiosynthesis of NR2B NMDA receptor antagonists and effected by a commercially available radiochemistry module. The in vivo evaluation of three radiotracers demonstrated minimal brain uptakes incompatible with the imaging of NR2B NMDA receptors in the living brain. Nevertheless, moderate radiometabolism was observed and, in particular, no radiodefluorination was observed which demonstrates the stability of the 3-position of the fluorine-18 atom. In conclusion, the 1,4-disubstituted 3-[18F]fluoropiperidine moiety could be of value in the development of other radiotracers for PET even if the evaluation of the NR2B NMDA receptor antagonists failed to demonstrate satisfactory properties for PET imaging of this receptor.

  为了开发用于正电子发射断层扫描（PET）示踪剂的新颖且有用的构建模块，我们研究了1,4-二取代的3-[18F]氟哌啶的放射性标记。实际上，3-氟哌啶已成为药物化学中含哌啶化合物的药效调控的有用构建模块。我们在具有供电子和吸电子N-取代基的取代哌啶上研究了放射性氟化。对于具有供电子N-取代基（如苄基或丁基）的情况，观察到了构型保持和令人满意的氟-18掺入产率，高达80％。在导致形成氨基甲酸酯或酰胺功能的吸电子N-取代基的情况下，掺入产率取决于4-取代基（2至63％）。该构建模块的放射性标记被应用于NR2B NMDA受体拮抗剂的自动放射合成，并通过商用的放射化学模块实现。对三种放射性示踪剂的体内评估显示，其脑摄取量极低，与在活脑中成像NR2B NMDA受体不兼容。然而，观察到了中等程度的放射性代谢，特别是未观察到放射性去氟化，这表明氟-18原子的3位点的稳定性。总之，1,4-二取代的3-[18F]氟哌啶部分可能对开发其他PET示踪剂有价值，即使NR2B NMDA受体拮抗剂的评估未能显示出适用于该受体PET成像的令人满意的特性。
• [EN] PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS CONTENANT DE LA PIPÉRIDINE ET LEURS UTILISATIONS
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2010080864A1

  公开（公告）日：2010-07-15

  A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I) wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

  一种预防和/或治疗代谢性疾病、脑血管疾病等的方法，包括向哺乳动物施用化合物的有效量，其化学式为(I)，其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂合物或前药。以及化学式(I-1)的新化合物：其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂合物或前药具有抗糖尿病作用和神经保护作用。因此，化合物(I)和化合物(I-1)在预防和/或治疗代谢性疾病如糖尿病、脑血管疾病如中风等方面是有用的。
• Novel diazepan derivatives
  申请人：Aebi Johannes

  公开号：US20070249589A1

  公开（公告）日：2007-10-25

  The invention is concerned with novel diazepan derivatives of formula (I) wherein A, X, R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.

  这项发明涉及式（I）的新型二氮杂环己烷衍生物，其中A、X、R3、R4、R5、R6、R8、R9、R10、R11、R12、R13、m和n的定义如描述和索赔中所述，以及其生理上可接受的盐。这些化合物是CCR-2受体、CCR-5受体和/或CCR-3受体的拮抗剂，可用作药物。
• Synthesis and Characterization of Enantiomerically Pure cis- and trans-3-Fluoro-2,4-dioxa-9-aza-3-phosphadecalin 3-Oxides as Acetylcholine Mimetics and Inhibitors of Acetylcholinesterase
  作者：Piergiorgio Lorenzetto、Michael Wächter、Peter Rüedi

  DOI：10.1002/hlca.201000457

  日期：2011.5

  were deduced from that of their precursors, the enantiomerically pure ethyl 1‐benzyl‐3‐hydroxypiperidine‐4‐carboxylates and 1‐benzyl‐3‐hydroxypiperidine‐4‐methanols which were unambiguously assigned. Being configuratively fixed and conformationally constrained phosphorus analogues of acetylcholine, the title compounds represent acetylcholine mimetics and are suitable probes for the investigation of

  标题化合物为P（3）轴向和P（3）赤道取代的顺式和反式构型9-苄基-3-氟-2,4-二氧杂-9-氮杂-3-磷酸钙素3-氧化物（ = 9-苄基-3-氟-2,4-二氧杂-9-氮杂-3-磷酸双环[4.4.0]癸烷3-氧化物= 7-苄基-2-氟六氢-4 H -1,3,2-二氧杂磷基制备[4,5 - c ]吡啶2-氧化物）（ee> 99％）并充分表征（方案2和4）。绝对构型由其前体，对映体纯的1-苄基3-羟基哌啶4-羧酸乙酯和1-苄基3-羟基哌啶-4-甲醇分配而得。作为乙酰胆碱的结构固定和构象受限的磷类似物，标题化合物代表乙酰胆碱模拟物，是研究与乙酰胆碱酯酶的分子相互作用的合适探针。通过动力学方法确定，所有化合物都是该酶的中度不可逆抑制剂。
• PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF
  申请人：Rodriguez Martha E.

  公开号：US20110275608A1

  公开（公告）日：2011-11-10

  A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

  一种预防和/或治疗代谢性疾病、脑血管疾病等的方法，包括向哺乳动物投与公式(I)化合物的有效量：其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂化物或前药。公式(I-1)的新化合物：其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂化物或前药具有抗糖尿病和神经保护作用。因此，公式(I)和公式(I-1)的化合物在预防和/或治疗代谢性疾病（如糖尿病）、脑血管疾病（如中风）等方面有用。